In a recent retrospective observational study, Liu et al. showed that short-term treatment with tofacitinib (for a median of 52.5 days) induced promising clinical efficacy in 47 out of 53 patients (88.7%) experiencing irAEs (including myocarditis, myositis, and hepatitis) during ICI therapies, mainly with anti-PD-1 antibody. The gene discussed is PDCD1; the disease is myositis disease.